New Market - April 3, 2015
AZ Drug on Swedish Market
AstraZeneca Pharmaceutical’s naloxegol or Moventig, is now available on the Swedish market, the first country in Europe since approval for the European market was granted in 2014. In mid- September 2014, naloxgel was approved for use in the U.S. under the name Movantik. It was launched on the US market this week. Naloxegol is intended […]
Collaboration - March 20, 2015
AstraZeneca, Daiichi Sankyo Ink Co-Commercialization Deal
AstraZeneca Thursday signed a co-commercialization agreement with Parsippany, N.J.-based Daiichi Sankyo, Inc. worth $825 million. According to the agreement, Daiichi Sankyo will pay AstraZeneca $200 million upfront and follow-up payments up to $625 million to handle manufacturing and sales of Movantik (naloxegol), a once-daily pill for people with opioid-induced constipation (OIC). AstraZeneca will oversee manufacturing […]
